Condition
Epileptic Syndromes
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
50.0%
-36.6% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results50% success
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Completed2
Terminated2
Recruiting1
Trial Success Rate
50.0%
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04048213Completed
The Becoming of Children With Doose Syndrome
NCT04912856Phase 3Terminated
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
NCT04639310Phase 3Terminated
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
NCT06223334RecruitingPrimary
Epileptic Syndromes in Infants and Early Childhood
NCT06222840CompletedPrimary
Electro-clinical Features and Functional Connectivity Analysis in SYN1 Gene Mutation-related Epilepsy
Showing all 5 trials